RNA-Seq analysis identifies to GATA3-AS1 as a lncRNA associated with resistance to neoadjuvant chemotherapy in locally advanced breast cancer patients

Purpose: Identified the expression profile of lncRNA associated to neoadjuvant chemotherapy response in 11 tumor of locally advanced breast cancer patients Methods: We implemented the transcriptomic analysis from 11 breast cancer samples by paired-end RNA-Seq, as a case-control study (responders vs nonresponders group). Differential expression analysis for lncRNA and mRNA were made to identify lncRNA as predictive biomarkers. Results: We identified the over-expressed lncRNA GATA3-AS1 in nonresponders group. Additionally, we identified the pathways were differentially expressed lncRNA and mRNA are associated in neoadjuvant chemotherapy response. Conclusion: we propose lncRNA GATA3-AS1 as a potential predictive biomarker for patients with LABC luminal B-like subtype that will not respond to neoadjuvant chemotherapy Overall design: Transcriptomic analysis of 11 tumor samples from locally advanced breast cancer mexican patients in a case-control study (responders vs nonresponders group), in order to identify lncRNA associated to neoadjuvant chemotherapy response.